EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California, San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extrace...
EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California, San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.